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Abstract
Activation of the glucocorticoid receptor (GR) by endogenous and synthetic glucocorticoids regulates
hundreds of genes to control regulatory networks in development, metabolism, cognition and inflamma-
tion. Elucidation of the mechanisms that regulate glucocorticoid action has highlighted the dynamic nature
of hormone signalling and provides novel insights into genomic glucocorticoid actions. The major factors
that regulate GR function include chromatin structure, epigenetics, genetic variation and the pattern of
glucocorticoid hormone secretion. We review our current understanding of the mechanisms that contrib-
ute to GR signalling and how these contribute to glucocorticoid sensitivity, resistance and side effects.
Key words: rhythms, pulsatile secretion, epigenetics, chromatin, glucocorticoid, genetic variation, glucocorticoid
sensitivity.
Introduction
Endogenous glucocorticoid steroid hormones—cortisol in
humans and corticosterone in rodents—act to regulate
transcriptional pathways in diverse cellular contexts to
regulate development, homeostasis, metabolism, cogni-
tion and inflammation. Since glucocorticoids have anti-
inflammatory and immunosuppressive properties, they
are frequently used to treat many inflammatory conditions,
from inflammatory arthritis and ulcerative colitis to asthma
and skin diseases, while pro-apoptotic properties make
them a major component of the treatment of many onco-
logical disorders. Unfortunately, however, long-term and/
or high-dose glucocorticoid administration is commonly
associated with side effects, from hyperglycaemia, weight
gain and hypertension to osteoporosis, depression and
decreased immunological function. Furthermore, patients
on glucocorticoids can develop reduced glucocorticoid
sensitivity and even resistance. Although the prevalence
of glucocorticoid resistance is unclear, in part due to poor
definitions, some reports suggest up to one-third of patients
with asthma [1], RA [2], ulcerative colitis [3] and SLE [4] show
altered glucocorticoid sensitivity [5]. Furthermore, 1030% of
patients with acute lymphocytic leukaemia are gluco-
corticoid resistant, with a higher rate of resistance develop-
ing in patients who have had a relapse of leukaemia [6].
The actions of glucocorticoids are predominantly medi-
ated through its receptor, the glucocorticoid receptor
(GR). Upon exposure to glucocorticoids, GR undergoes
a structural conformational change that drives transloca-
tion from the cell cytoplasm into the nucleus. Once in the
nucleus, ligand-bound GR is available to interact with
regulatory elements in the genome [712], where it is
known to induce and repress transcription of hundreds
of target genes [12, 13]. The expression of GR, a DNA-
binding transcription factor of the nuclear receptor super-
family, is nearly ubiquitously expressed [14]. Its biological
activities result predominately from interactions with chro-
matin. Chromatin is a complex of DNA with DNA packa-
ging proteins called nucleosomes. Nucleosomes are
made up of histone proteins, which act to compact the
length of DNA into the nucleus. The availability of binding
sites for GR in the DNA necessitates engagement with
chromatin to access the underlying DNA concealed by
nucleosomes. Through mechanisms that alter chromatin
structure via histone modifications, and structural remo-
delling, as well as DNA methylation, the accessibility of
the DNA sequence can be modified [15]. These factors
do not alter the DNA sequence, but can provide epi-
genetic memory of transcriptional states [16], that is,
non-genetic mechanisms that are heritable across cell
division and generations. In this review we discuss the
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Wcomplexity of glucocorticoid signalling, in the context of
GR interactions with chromatin, and the factors that con-
tribute to steroid sensitivity, resistance and unwanted side
effects.
Physiological and pathological patterns
of glucocorticoid secretion
The secretion of glucocorticoid hormones from the adrenal
gland is under the control of adrenocorticotropic hormone
(ACTH) from the anterior pituitary and corticotropin-
releasing hormone (CRH) from the hypothalamus.
Additionally, the circulating level of cortisol is regulated
through its negative feedback activity on both ACTH and
CRH release [17]. These regulatory loops act to maintain
normal physiological levels of hormone [17]. The pattern of
cortisol secretion is classically circadian, with peak secre-
tion early in the morning in anticipation of waking-related
activities (Fig. 1). This circadian pattern, however, is actu-
ally made up from an underlying ultradian pattern of
hormone secretion, with the largest pulses of secretion
occurring early in the morning (Fig. 1). This ultradian pat-
tern is evolutionarily conserved across mammals, implicat-
ing pulsatility as an important feature of glucocorticoid
signalling [18, 19].
The pattern of glucocorticoid ultradian pulsatility is highly
variable in frequency and amplitude. Studies in the rat
show sex-specific differences, and both genetic and epi-
genetic modification of ultradian pattern and glucocortic-
oid response to stress [17, 18]. Altered patterns of
glucocorticoid secretion also occur in response not only
to acute stressors, but also to chronic stress states such
as obstructive sleep apnoea in man [20], and of particular
importance for this review, immune-mediated disease
both in man and in experimental animal models [21, 22].
The significance of the hypothalamic-pituitary-adrenal
(HPA) axisimmune interaction has been appreciated
for many years [23]. As inflammation drives increased
production of anti-inflammatory glucocorticoids, the
HPAimmune axis acts in a classical negative feedback
loop [24]. Evidence from animal experiments strongly
implicates the HPA axis in regulating inflammation
[2527]. Accordingly, disruption of the HPA axis by
adrenalectomy results in increased disease severity in
an experimental model of adjuvant-induced arthritis
[2729]. Significantly, dysregulated rhythms of endo-
genous glucocorticoid secretion are a key characteristic
of inflammation-associated chronic activation of the
HPA axis, with loss of circadian rhythm [30] and altered
ultradian rhythm [22].
There is also evidence that chronic exposure to altered
glucocorticoid secretion following chronic stress can result
in glucocorticoid resistance [31, 32]. Indeed, there is evi-
dence that suggests this can be a feature of RA [33]. It is
clear, therefore, that there are dynamic patterns of gluco-
corticoid secretion that respond to both physiological and
pathological states, and suggest that during some of these
pathological states the aberrant glucocorticoid secretory
pattern could alter glucocorticoid signalling and resistance.
Another situation in which there is an altered pattern
of plasma glucocorticoids is found during glucocorticoid
therapy—either when it is given therapeutically as an anti-
inflammatory or immune modulator, or when it is given as
replacement therapy in Addison’s disease, congenital
adrenal hyperplasia or hypopituitarism. Unfortunately,
current treatment protocols are unable to reproduce either
the normal ultradian pattern of hormone secretion or the
pre-awakening circadian rise of hormone secretion, al-
though new delayed-release preparations are being de-
veloped that may improve the circadian pattern [34].
There is now considerable evidence that pulsa-
tile changes in plasma glucocorticoid levels result in
gene pulsing mediated by transient GR activation [35,
36]. Pulsatile patterns therefore exert homeostatic con-
trol through GR-dependent transcription regulation that
rapidly responds to circulating hormone levels (Fig. 1)
[36, 37]. Conversely, constant non-oscillatory hormone
levels result in continuous transcription, aberrant mRNA
accumulation and abnormal protein levels [36]. We sug-
gest that a treatment regimen comprising pulsatile gluco-
corticoid patterns over a circadian rhythm might confer
therapeutic benefits while minimizing undesired side
effects.
Genomic actions and cell specificity
of GR
The organization of DNA in eukaryotic cells as chromatin
permits compaction of DNA into the nuclear space.
DNA-binding factors, such as GR, must overcome the
chromatin barrier to access the underlying DNA se-
quences in regulatory elements to drive transcription con-
trol. Accessibility of chromatin across the genome,
however, is highly variable. Recent genome-wide data
have shown that active regulatory elements, such as pro-
moters and enhancers, are openly accessible chromatin
domains [38, 39].
Upon ligand activation, GR acts as a sequence-specific
transcription factor, binding to a consensus DNA motif,
the glucocorticoid response element (GRE), to drive
gene expression [40]. Despite widespread expression,
GR regulation of transcriptional programmes is highly
cell and tissue specific, binding to distinct genomic
loci in different cellular contexts [1012]. With hundreds
of different cell types in complex eukaryotes containing
identical genomic content, the selection of specific
binding sites in different cells has remained an important
question. Chromatin has emerged over the past few dec-
ades as a critical player in transcriptional regulation.
Control of transcription is thought to occur through alter-
ing chromatin structure or epigenetics by mechanisms
such as chromatin remodelling, DNA methylation and
modifications of histones. Indeed, the accessibility of
chromatin has been shown to direct the binding of GR
to regulatory elements [10, 11]. Importantly, cell-specific
GR-binding events are associated with cell-specific
regulatory elements marked by accessible chromatin
[10, 11]. The vast majority of interactions between GR
404 www.rheumatology.oxfordjournals.org
Simon C. Biddie et al.and chromatin have been shown to be predetermined
before hormone, that is, GR predominantly binds to
the genome at chromatin where the DNA is accessible
before hormone and thus independent of hormone
action. These observations implicate open chromatin as
a major player in GR binding and define the cell-specific
landscape of GR action, suggesting the cellular context
contributes to the pre-setting of cell-specific hormone
action [11].
In addition to the direct actions of GR on DNA, the re-
ceptor interacts with a large cohort of other DNA-binding
factors [41]. Known cooperative proteinprotein
interactions include nuclear factor 1 (NF1), CCAAT/enhan-
cer-binding proteins (C/EBP) and octamer transcription fac-
tors [4244]. Through interacting with these accessory
factors, GR-dependent transcription is thought to be
dynamic and variable, including cell-specific interactions
with accessory factors (Fig. 2A) [11]. Therefore the regu-
lation of cell-specific genes by glucocorticoids is depend-
ent on the expression and activity of interacting partners.
These interactions allow diversity in regulatory control
over activated genes and also mean that alterations in
accessory factor activity could modify the sensitivity and
resistance to hormone action.
FIG.1Glucocorticoid pulsatility drives transient activation of GR-responsive genes. Murine serum corticosteroid (cort)
levels rise in anticipation of the active phase. Hormone levels follow a circadian pattern, although the underlying pattern
of hormone secretion is ultradian, where glucocorticoids are released approximately every hour. During a pulse, exposure
to hormone drives GR translocation into the nucleus, where it binds to genomic elements to drive transcription. Hormone
troughs result in GR dissociation from chromatin, releasing the receptor into the nucleoplasm ready to initiate tran-
scription during further rises in hormone levels. The dynamics of the receptor and hormone secretion patterns allow rapid
response to rapidly changing cellular and physiological conditions.
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GR is known to positively and negatively regulate tran-
scription [12, 13, 45]. GR-dependent induction and re-
pression of genes play critical roles in metabolic,
circadian and inflammatory signalling networks.
Inductive actions of homodimeric GR are mediated
through direct binding to DNA at GREs [46, 47].
Upon DNA binding, GR promotes the recruitment of
chromatin-modifying co-factors and the transcriptional
machinery, including RNA polymerase II (Pol II) to drive
transcription [48]. The recruitment of co-factors such as
Brg1 and the histone acetyltransferase (HAT) CBP/p300
by GR alters chromatin structure to an accessible state
poised for gene activation (Fig. 2) [49, 50]. For instance,
the chromatin-remodelling activity of Brg1 is thought to
alter the positioning and composition of nucleosomes,
while HATs acetylate the histones H3 and H4 [5153].
Both mechanisms are thought to alter the contacts
between nucleosomes and DNA, exposing the DNA to
regulatory factor binding [54, 55].
The binding of GR to chromatin and the hormone-
dependent remodelling of chromatin is highly dynamic.
Using fluorescently tagged receptor coupled with photo-
bleaching experiments to monitor recovery times, GR was
found to rapidly cycle chromatin on and off in living cells in
seconds to minutes [56, 57]. In contrast to the classic
model where binding of transcription factors to DNA is
represented by stable complexes, the current model sug-
gests transient transcription factor binding to chromatin
[37]. Here, GR rapidly engages and disengages the chro-
matin template, during which Brg1-dependent chromatin
remodelling concomitantly undergoes dynamic exchange
[58, 59].
FIG.2Cell- and gene-specific actions of GR. (A) Chromatin accessibility is a major determinant of receptor binding to
chromatin. Active genes are shown to have accessible DNA and acetylated (Ac) histones. Genes induced by GR require
homodimers that bind directly to DNA at GREs. Hormone-dependent gene repression is mediated by homomeric GR
proteinprotein interactions with other transcription factors such as AP1. (B) Transcription output in the presence of
constant hormone is kinetically diverse. Induced and repressed genes can undergo phases of up- and down-regulation.
Induced genes can be continuously (blue) or transiently (green) induced, or induced to a maintained plateau state (red).
Similarly, repressed genes can be continuously (black) or transiently (purple) repressed, or repressed in a plateau state
over time (orange). Lines represent classes of genes. The kinetics of transcription is therefore gene specific. Cort:
corticosterone/cortisol, Ac: acetylation.
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slower cyclical activity is imposed on GR by the ultradian
rhythm of ligand exposure, a phasic GR action regulated
by the deterministic mechanism of the ligand pulse pat-
tern [60]. The phasic action of GR is evident as cyclical
shifts in the net equilibrium of GR at regulatory elements
towards a bound state [61]. Precisely tracking the rhythm
of pulsatile hormone and cyclical GR activity are cyclical
changes in recruitment of the HAT complex CBP/P300.
Phasic CBP/P300 recruitment results in rapid and revers-
ible increases in histone acetylation at regulatory regions
in glucocorticoid-target genes, again in phase with the
ultradian hormone pattern [61, 62]. As histone acetylation
is associated with recruitment of chromatin remodelling
factors of the SWI/SNF family such as Brg1, allowing
access of Pol II and auxiliary transcription machinery to
the transcription start site (TSS), it is often closely corre-
lated to transcriptional activity [52]. Consistent with this,
Pol II recruitment also exhibits ultradian rhythm-directed
cyclical activity at the TSS of glucocorticoid pulse regu-
lated genes. These cyclical changes in acetylation status
of glucocorticoid-target genes, and the concomitant
cycling of GR, its regulatory co-factors and Pol II at the
TSS, are therefore proposed as the mechanism for tem-
poral regulation of the gene-pulsing phenomenon asso-
ciated with ultradian glucocorticoid rhythm.
Therefore the two components—the stochastic recep-
tor and the deterministic ligand secretory pattern—appear
to have evolved together to establish and maintain an
optimal system of transcriptional regulation. The dynamic
action is not unique to GR, extending to other transcrip-
tion factors, and represents a general mechanism that
permits continuous sampling of the cellular milieu [37]. In
the case of GR, the mechanism accommodates fluctu-
ations in hormone levels and thus can rapidly respond
to physiological and pathological glucocorticoid secretory
patterns. The general requirement for accessible chroma-
tin also suggests that chromatin structure, and factors
that regulate chromatin accessibility, could influence hor-
mone sensitivity and resistance.
Repressive actions of the GR
The interaction between GR and other transcription fac-
tors such as activator protein 1 (AP1) and nuclear factor
kappa B (NF-kB) is known to repress gene activity through
transrepression [45, 6365]. GR-dependent perturbation
of these pro-inflammatory factors is thought to occur
through proteinprotein interactions [45, 63, 64]. While
transactivation requires GR homodimers, transrepression
is mediated through GR monomers (Fig. 2A) [66, 67].
Knock-out of GR from mouse renders them unviable, al-
though interestingly, GR dimerization mutants, where GR
cannot form homodimers, are viable, suggesting that
transrepression by monomeric GR is sufficient for survival
[68]. In addition, GR and AP1 can interact at composite
elements, where each factor binds directly to DNA, but
their proximity results in hormone-dependent modulation
of AP1 action [45]. The interactions between GR and
pro-inflammatory factors involve altered recruitment of
co-regulators that directly inhibit Pol II elongation [69,
70]. Additionally, GR is a target of histone deacetylase 2
(HDAC2), resulting in de-acetylation of the receptor and
preferential interactions with NF-kB [71].
The activity of NF-kB and AP1 are critical to numerous
inflammatory conditions, including arthritis and asthma
[71, 72]. In addition to transrepression, gene induction
contributes to anti-inflammation by inducing the expres-
sion of immune modulators in some cell types, including
the negative regulator of NF-kB, IkB-a [73, 74]. The re-
pressive action of glucocorticoids on NF-kB and AP1 ac-
tivity is therefore context dependent, with the sensitivity of
glucocorticoid action dependent on the cell type and the
expression and activity of pro-inflammatory proteins and
co-regulators. For example, over-expression of AP1 has
been shown to impair GR repression, contributing to re-
sistance [75]. Furthermore, GR-dependent induction of
mitogen-activated protein kinase phosphatase 1 (MKP1)
and glucocorticoid-induced leucine zipper (GILZ) have
anti-inflammatory actions, where disruption of their regu-
lation alters hormone sensitivity in RA [7678]. In respira-
tory conditions such as chronic obstructive pulmonary
disease (COPD), reduced expression and activity of
HDAC2 is associated with increased inflammatory gene
expression and confers glucocorticoid resistance [71].
The design of receptor ligands that dissociate
GR-mediated induction and repression are of much inter-
est, with the aim of reducing side-effect profiles [79].
However, the mechanisms regulating GR gene induction
and repression are not always clear, as GR can also
induce AP1 activity [45]. The effect of GR on AP1 activity,
whether positive or negative, is thought to depend on the
composition of the AP1 complex, a multi-subunit family
that can form homo- and heterodimers, and the DNA se-
quence of regulatory elements [80]. Furthermore, some
side-effect profiles are related to interactions between
GR and pro-inflammatory factors. Indeed, the osteo-
porotic side effect of glucocorticoids is thought to involve
GR and AP1 interactions that inhibit osteoblast differenti-
ation [81]. It is therefore unclear what role selective GR
modulators will have in the clinic, although the character-
ization of some compounds has suggested reduced side
effects, including osteoporosis [82]. Their clinical efficacy
and safety will need to be extensively evaluated.
The distinction between GR inductive and repressive
effects is a conventional, but limited, definition. Using
genome-wide microarray approaches to evaluate gene
expression over a long time course, the regulation of
genes by GR displays complex kinetics [13]. In contrast
to simple induction or repression, hundreds of genes
undergo positive and negative regulatory phases in the
presence of constant hormone (Fig. 2B) [13]. Over hours
of constant glucocorticoid exposure, induced genes can
be rapidly induced to a plateau phase, transiently induced
or slowly and continuously induced. Repressed genes
also exhibit similar kinetics patterns, showing rapid re-
pression that plateaus transient repression or continuous
repression (Fig. 2B). These classes of kinetic gene activity
suggest gene-specific regulatory control by hormones.
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exposure pattern, constant or pulsatile, and independent
of glucocorticoid type, endogenous or synthetic, although
this has not been definitively shown. These kinetic impli-
cate modifications to chromatin or regulatory factors,
such as GR and recruited co-factors that act to modify
the transcriptional output in a gene-specific manner. For
instance, the acetylation of HDAC1 upon GR recruitment
is thought to contribute to refractory phases in induced
gene transcription [83]. The complexity and dynamics
of glucocorticoid action are only beginning to be under-
stood. The relevance of kinetic patterns of GR-dependent
gene expression in vivo is not yet clear, particularly in
underlying circadian and pulsatile glucocorticoid
secretory modes. Nevertheless, we propose that the inter-
play between non-receptor transcription factors and
co-regulators plays a critical role in GR action and
provides a mechanism of plasticity in response the
physiological and pathological signals.
Genetic and epigenetic factors in
glucocorticoid sensitivity and resistance
Primary generalized glucocorticoid resistance is a rare
condition associated with compensatory increases in
plasma ACTH and cortisol [5]. Patients present with fea-
tures of mineralocorticoid and adrenal androgen excess
due to concomitant adrenal hyperplasia and elevated ad-
renal steroids [84]. The condition results from familial or
sporadic mutations of the GR gene, resulting in impaired
expression, ligand binding or nuclear translocation [84].
Mutations in co-regulator genes might, in principle, also
confer glucocorticoid resistance. Indeed, defects in the
steroid receptor co-activators (SRCs) were observed in
a pan-steroid resistance syndrome [85]. Generally, genet-
ic mutations are unlikely to contribute to resistance affect-
ing specific cells in common inflammatory conditions such
as arthritis. Sporadic genetic mutations are more likely in
rapidly dividing cells, particularly cancers. GR mutations
have been associated with leukaemic cell lines associated
with resistance to chemotherapeutic apoptotic effects of
glucocorticoid, although their contribution to resistance in
patients is contentious [86]. Similarly, mutations in Brg1
have been found in lung cancers, and as an important
co-factor for GR action, mutations in Brg1 could contrib-
ute to glucocorticoid resistance [87].
Interestingly, one-third of the normal population display
in vitro resistance to glucocorticoids and will predict-
ably fail to respond to clinical treatment [5]. Single nu-
cleotide polymorphisms (SNPs) contribute extensively
to human variation and possible glucocorticoid action.
Polymorphisms of the CS-binding globulin (CBG),
Toll-like receptors (TLRs) and macrophage migration in-
hibitory factor (MIF) genes are associated with altered
serum cortisol levels and glucocorticoid sensitivity
[5, 32]. At the level of DNA binding, SNPs have also
been shown to cause aberrant transcription factor recruit-
ment [88]. Whole-genome analyses of the DNA-binding
factors NF-kB and CCCTC-binding factor (CTCF) have
shown that genetic variation extensively contributes to dif-
ferential factor occupancy [89, 90]. These observations
suggest that SNPs could alter GR-binding patterns and
alter sensitivity to glucocorticoids at specific target genes.
Additionally, variation in the GRE sequence modifies GR
structure by acting as an allosteric modulator [91]. The
structural difference might promote specific interactions,
with co-regulators affecting GR-dependent gene regula-
tion (Fig. 3A). Therefore SNPs in GREs could modify GR
action in a gene- and individual-specific fashion.
DNA methylation, an epigenetic mechanism associated
with chromatin condensation and gene silencing, has
been shown to modify GR gene expression [92]. In an
experience-dependent manner, DNA methylation of the
GR promoter in specific brain regions is associated with
reduced GR expression levels, and consequently resist-
ance to glucocorticoids. In rodent models, deprivation
of maternal nurturing increases DNA methylation of
the GR promoter in the hippocampus, resulting in trans-
FIG.3Genetic and epigenetic mechanisms in GR action.
(A) DNA is an allosteric modulator, altering the structure of
the receptor when bound to DNA. SNPs (blue) at GREs
(red) could alter the interactions with co-factors by
influencing GR structure. The effects might contribute to
gene- and individual-specific gene regulation. (B) DNA
methylation, an epigenetic mechanism, acts to silence
gene transcription by altering chromatin structure.
Individual-specific experiences, such as maternal
nurturing, can alter DNA methylation patterns, producing
expression patterns heritable across generations. The
reduction in GR expression causes resistance to hormone
action in specific tissues. Cort: cortisol.
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[92]. The observation suggests that DNA methylation is dy-
namic and programmable. Similarly, GR promoter methy-
lation was observed in post-mortem hippocampi of
suicide victims with a history of child abuse, suggesting
interplay between methylation status and individual ex-
perience [93]. Experience-dependent epigenetic program-
ming might therefore play a role in other physiological and
pathological conditions. Genetic and epigenetic variation
is therefore likely to contribute to glucocorticoid sensitiv-
ity, although the incidence of these variants in the general
population is not fully understood.
Concluding remarks
The diverse and disparate transcription networks regu-
lated by glucocorticoids result from ubiquitous receptor
expression, but cell-specific actions [11]. In particular,
the anti-inflammatory and immunosuppressive effects
are extensively exploited clinically, making glucocorti-
coids one of the most commonly prescribed classes
of therapeutics. The chronic nature of many of the inflam-
matory conditions, including RA, SLE, asthma and
IBD, requires long-term glucocorticoid administration.
The treatment paradigms frequently result in side effects
that reduce their tolerance and, not uncommonly, induce
the development of glucocorticoid resistance [5].
Factors that contribute to the dynamics and plasticity of
glucocorticoid signalling, from the patterns and levels of
hormone secretion to the binding of receptor at specific
DNA sequences, represent potential mechanisms regulat-
ing sensitivity and resistance. Technological advances in
molecular biology such as genome-wide techniques have
advanced our understanding of the molecular mechan-
isms of GR [11]. It is vital that our current understanding
is translated into physiological conditions and into the
clinic.
Advances in drug design and therapeutics principles
should extend beyond dissociating the desired
anti-inflammatory effects and reducing side effects,
targeting cell-specific functions of glucocorticoids.
High-throughput technologies, including genomics, prote-
omics and metabolomics, as well as chemical and RNA
interference screening, could be employed to discover
important and novel targets in glucocorticoid action in
multiple cell types under different physiological and
pathological backgrounds. These studies will be crucial
for understanding the networks regulating gluco-
corticoid action, sensitivity and resistance in health and
disease.
Rheumatology key messages
. Glucocorticoids are secreted in an ultradian pulsa-
tile pattern.
. Chromatin structure or epigenetics is critical for
cell-specific glucocorticoid actions.
. Regulation of glucocorticoid responsive genes de-
pends on interaction with interacting factors.
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